Low-grade lung adenocarcinoma of fetal lung type, which is well characterized by its unique clinicopathologic and molecular features, is recognized as a distinct variant of lung cancer. In contrast, high-grade lung adenocarcinoma with fetal lung-like morphology (HG-LAFM) has not been studied widely. To characterize this subset better, we analyzed 17 highgrade adenocarcinomas with at least focal component resembling a developing epithelium in the pseudoglandular phase of the fetal lung. These rare (ca. 0.4%) carcinomas occurred predominantly in elderly men with a heavy smoking history, who showed elevated serum a-fetoprotein in 4 of 5 cases tested. Histologic examination revealed a fetal lung-like component as a focal finding accounting for 5% to 60% of the total tumor volume. It was invariably admixed with tissues having a morphology not resembling that of a fetal lung. A coexisting nonfetal lung-like element was quite heterogenous in appearance, showing various growth patterns. However, clear-cell (88%), hepatoid (29%), and large cell neuroendocrine carcinoma (24%) histology seemed overrepresented. HG-LAFM was characterized immunohistochemically by frequent expression of a-fetoprotein (41%), glypican-3 (88%), SALL-4 (59%), neuroendocrine markers (82%), CDX-2 (35%), and p53 (65%). HG-LAFM was molecularly heterogenous in that EGFR or KRAS mutation was observed in 22% of cases tested for both. Our data indicate that HG-LAFMs might form a coherent subgroup of lung adenocarcinomas. However, the uniformly focal nature of the fetal lung-like element, widely diverse coexisting non-fetal lung-like histology, and inhomogenous molecular profiles lead us to believe that HG-LAFM is best regarded as a morphologic pattern showing characteristic association with several clinicopathologic parameters rather than a specific tumor entity. FIGURE 2. Immunoprofiles of 17 HG-LAFMs. The left halves of the 2 boxes for each molecule show the results in fetal lunglike component. The right halves show the result in the coexisting non-fetal lung-like component. A filled box represents positive staining. An empty box means a negative result. F denotes a fetal lung-like component; NF, a non-fetal lunglike component; Synapt, synaptophysin; Ch-A, chromogranin A; NCAM, neural cell adhesion molecule; TTF-1, thyroid transcription factor-1.
L ung cancer is the leading cause of tumor mortality worldwide. 1 Adenocarcinoma, the most common subtype, is well known for its diverse morphologic appearance. 2 Primary lung adenocarcinomas can, but rarely, exhibit morphologic features resembling those of a developing fetal lung. [3] [4] [5] [6] [7] [8] In 1998, Nakatani et al 8 reviewed 16 lung carcinomas with such features and subdivided them into low-grade and high-grade forms. Low-grade adenocarcinoma of fetal lung type (also known as pulmonary endodermal tumor resembling fetal lung 4 ) was characterized by complex glandular structures resembling a developing epithelium in the pseudoglandular phase of the fetal lung, low nuclear atypia, and morule formation. In contrast, aside from the fetal lung-like epithelial character, the high-grade form was found to show prominent nuclear atypia, a lack of morules, a transition to conventional adenocarcinoma, and necrosis. This dichotomous classification was later applied to biphasic tumors conventionally known as "pulmonary blastoma." They were subdivided into "classic" type associated with low-grade fetal lung-like epithelium and "blastomatoid variant of carcinosarcoma" associated with high-grade fetal lung-like epithelium. 9 Subsequent molecular studies have revealed that the low-grade adenocarcinoma of fetal lung type (and its biphasic variant) was characterized by b-catenin gene mutation leading to aberrant nuclear/cytoplasmic b-catenin expression. [9] [10] [11] Currently, low-grade adenocarcinoma of fetal lung type is recognized as a distinct subgroup of lung cancer in the current World Health Organization (WHO) classification by the name of well-differentiated fetal adenocarcinoma. 2 In contrast, the high-grade form, hereinafter termed high-grade lung adenocarcinoma with fetal lung-like morphology (HG-LAFM) in this article, has not been investigated widely. No systematic study of this subset has been undertaken since the original proposal by Nakatani et al, 8 and it remains unclear whether HG-LAFM is a distinct variant of lung cancer.
In this study, we examined clinicopathologic, immunohistochemical, and molecular features of 17 cases of HG-LAFM retrospectively to elucidate this morphologic subset and to determine whether HG-LAFM deserves designation as a specific variant of lung adenocarcinoma.
MATERIALS AND METHODS

Case Selection
This study was approved by the review board of each participating institution. HG-LAFMs were sought electronically from the respective surgical pathology archives of the National Cancer Center Hospital (Tokyo), The University of Tokyo Hospital (Tokyo), Mitsui Memorial Hospital (Tokyo), and Saitama Medical University (Saitama). The search was facilitated by key words such as "fetal," "primitive," and "immature." Fetal lunglike morphology was defined by complex glandular architecture composed of tall columnar cells that displayed supranuclear and/or subnuclear clear cytoplasm resembling a developing epithelium in the pseudoglandular phase of the fetal lung. Occasional papillary infoldings were allowed. The oval-shaped nucleus in each constituent tumor cell was typically aligned as perpendicular to the basement membrane. The apical border of tumoral glands was flat rather than interrupted by apical snouts. The nuclear grade was high. We required at least focal area of unequivocal fetal lung-like morphology for inclusion in this study. Two low-grade adenocarcinomas of fetal lung type (1 monophasic and 1 biphasic) in the archives were excluded. The search ultimately identified 17 cases of HG-LAFM, which accounted for ca. 0.4% of the >4000 primary lung cancer cases that had been surgically resected at the participating institutions.
Clinicopathologic Examination
Medical records were reviewed for demographic data, smoking history, serum a-fetoprotein (AFP) level when available, and follow-up information. Tumors were staged according to the TNM system. 12 All the tumors had been sampled adequately, fixed in 10% formalin, embedded in paraffin, cut into 4-mm-thick sections, and stained with hematoxylin and eosin for routine pathologic examination. All available glass slides were reviewed by 2 or 3 pathologists (S.M., A.G., and A.Y.). The amount of fetal lung-like element was evaluated as a percentage of the total tumor volume. Coexisting components that did not resemble developing fetal lung were also assessed and were classified on the basis of WHO guidelines. 2 The conventional adenocarcinoma component was characterized further by the growth pattern (lepidic, papillary, acinar, and solid) according to a recent recommendation. 13 In addition, we devoted attention to the presence or absence of hepatoid and clear-cell patterns and recorded these patterns separately. Although unrecognized in the present WHO scheme, a hepatoid pattern in lung adenocarcinoma was previously documented [14] [15] [16] [17] and was defined by solid to trabecular growth of tumor cells having eosinophilic cytoplasm, thereby simulating hepatocellular carcinoma. A clear-cell pattern indicated tumor cells showing significantly clear cytoplasm irrespective of the growth pattern. 18 Because fetal lung-like tumor cells harbored clear cytoplasm by definition, we considered only non-fetal lung-like element with clear cytoplasm as a clear-cell pattern for evaluation. The relative amount of each non-fetal lung-like histologic pattern was expressed as a percentage of the total tumor volume. Lymphovascular invasion, pleural invasion, and necrosis were assessed. Metastatic tumor tissues in lymph nodes were also evaluated when available.
Immunohistochemistry
For immunohistochemical staining, primary antibodies for AFP, glypican-3 (GPC-3), SALL-4, synaptophysin, chromogranin A, neural cell adhesion molecule, thyroid transcription factor-1 (TTF-1), CDX-2, p53, and b-catenin were used ( Table 1 ). Sections of 4 mm thickness from each block of the tumor tissue were stained using an automated stainer (Ventana Benchmark; Ventana Medical Systems Inc., Tucson, AZ) along with appropriate positive and negative controls.
All samples were evaluated and scored by 2 pathologists (S.M. and A.G.) without knowledge of clinicopathologic data. Staining of >1% of tumor cells was required for the positive designation except for p53, in which nuclear staining of >10% of tumor cells was considered positive.
Molecular Analysis
We performed a mutation analysis of epidermal growth factor receptor (EGFR) to detect deletion in exon 19 and point mutation in exon 21 (L858R) and of KRAS exon 2 (codons 12 and 13) and exon 3 (codon 61) by highresolution melting analysis. DNA was extracted from archived formalin-fixed or methanol-fixed, paraffin-embedded tissues using the QIAamp DNA Micro Kit (Qiagen Inc., Valencia, CA), following the manufacturer's instructions. Polymerase chain reaction was performed to amplify exons 19 and 21 of EGFR and exons 2 and 3 of KRAS using LCGreen I (Idaho Technology, Salt Lake City, UT) on a thermal cycler. Primers for EGFR analysis were designed as described previously. 19 Primers for KRAS exon 3 analysis were commercially available (Idaho Technology), and primers for KRAS exon 2 (92 bp) were published previously by others. 20 An additional set of primers for KRAS exon 2 (62 bp) was designed by one of the authors (K.Y.). The primer sequences are presented in Table 2 . These polymerase chain reaction products were analyzed using the LightScanner platform (Idaho Technology). Data were acquired and analyzed using the accompanying software (Idaho Technology). After the normalization step, melting curve shapes of the tumor samples and control samples were compared. Human Genomic DNA (Roche Diagnostics Corp., Indianapolis, IN) was used as the negative control sample with wild-type EGFR and KRAS. All analyses were performed in a blinded manner to the clinicopathologic data.
Statistics
Three-year and 5-year overall survival and diseasefree survival rates were calculated with the Kaplan-Meier method using software STAT View for Windows, ver. 5 (SAS Institute Inc., Cary, NC).
RESULTS
Clinical Characteristics
The clinical characteristics of HG-LAFMs are presented in Table 3 . HG-LAFM almost exclusively occurred in men (16 men, 1 woman). The patient ages ranged from 40 to 75 years (median, 64.2 y). Except for 2 patients whose smoking history was unknown, all the patients had been heavy smokers with exposure of >20 pack-years (median, 54.9 p-y). Three patients were symptomatic at presentation with cough (cases 3 and 4) or chest pain (case 1). Serum AFP level was available in 5 cases, and it was elevated in 4 of them (case 8, 8720 ng/ mL; case 12, 19 ng/mL; case 13, 16 ng/mL; case 17, 24 ng/ mL, normal range: <10 ng/mL). All patients were treated with lobectomy and standard lymph node dissection with a curative intent. No postoperative complication was recorded. Nine patients received postoperative chemotherapy. None received preoperative chemotherapy. The pathologic stages were I in 7, II in 6, and III in 4 cases. Follow-up data were available for all patients with duration of 1 to 85 months (median, 29.3 mo). Six patients developed distant metastases (case 1, adrenal; case 5, adrenal and bone; case 6, brain; case 10, brain and adrenal; case 11, lung; case 12, liver), and an additional patient had a metastasis to hilar lymph nodes (case 14) after surgery. Three-year and 5-year disease-free survival rates were 48.6% and 48.6%, respectively, and 3-year and 5-year overall survival rates were 71.4% and 53.6%, respectively.
Histopathologic Findings
The histologic characteristics of HG-LAFMs are presented in Table 3 and are shown in Figure 1 . The tumors measured 1.9 to 9.5 cm (average, 5.0 cm). All the 
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Primer Name Sequence Amplicon Size 17 tumors showed at least focal area resembling fetal lung epithelium by selection criteria (Figs. 1A, B ). The fetal lung-like component accounted for 5% to 60% (average, 25%) of the total tumor volume. None of the 17 tumors consisted entirely of fetal lung-like morphology. No tumor showed morule formation. The coexisting non-fetal lung-like components consisted of conventional adenocarcinoma that displayed various patterns including lepidic (6 cases, 35%), papillary (14 cases, 82%), acinar (14 cases, 82%), and solid (8 cases, 47%) patterns (Fig. 1C ). In addition to such conventional patterns, a hepatoid pattern was identified in 5 cases (29%, Fig. 1D ) and clear-cell component (exclusive of fetal lung-like element) was observed in 15 cases (88%; Fig. 1E ). Four cases had a large cell neuroendocrine carcinoma (LCNEC) component (cases 3, 4, 6, and 8; Fig. 1F ). None of the 17 cases harbored squamous cell or small cell differentiation. None was a biphasic tumor with sarcomatoid element. Lymphovascular and pleural invasions were identified in 14 and 11 cases, respectively. Necrosis was identified in all cases, and 13 cases (76%) showed grossly visible massive necrosis. Lymph node metastasis was identified in 6 cases (35%), of which 4 lesions showed fetal lung-like morphology.
Immunohistochemical Findings
Immunostaining results are presented in Figures 2  and 3 . Both fetal lung-like and coexisting non-fetal lunglike components were often positive for oncofetal proteins such as AFP (Fig. 3A) , GPC-3 (Fig. 3B) , and SALL-4 ( Fig. 3C) . These oncofetal proteins were more frequently positive in the non-fetal lung-like component, particularly in the clear-cell and hepatoid patterns, than in the fetal lung-like component. Specifically, the fetal lung-like component was positive for AFP, GPC-3, and SALL-4 in 29%, 76%, and 53%, respectively, whereas the non-fetal lung-like component labeled for these markers in 41%, 88%, and 59%, respectively. Similarly, at least 1 of 3 neuroendocrine markers (ie, synaptophysin, chromogranin A, and neural cell adhesion molecule) was positive in most (82%) cases, and it was more frequently positive in the non-fetal lung-like component (82%) than in the fetal lung-like component (65%) (Fig. 3D ). Thyroid transcription factor-1, CDX-2, and p53 were positive in 41%, 35%, and 59% of fetal lung-like components, respectively; they were positive in 53%, 35%, and 65% of non-fetal lung-like component, respectively (Figs. 3E, F). No nuclear or cytoplasmic aberrant expression of b-catenin was observed in any of the 17 cases.
Molecular Characteristics
Molecular characteristics of HG-LAFMs are presented in Table 4 . Mutation analyses of EGFR and KRAS genes were performed in 14 and 9 cases, respectively. One case harbored L858R mutation of EGFR, and another showed KRAS mutation in either codon 12 or 13. The remaining cases tested were of wild type for both EGFR and KRAS.
DISCUSSION
This comprehensive study of HG-LAFMs clarified their clinicopathologic characteristics and highlighted its difference from the reported traits of low-grade adenocarcinoma of fetal lung type. 8, 11 In addition to an unfavorable prognosis inherently attached to high tumor grade, the differences include the following. First, HG-LAFMs predominantly occurred in old men with a consistent heavy smoking history, unlike low-grade carcinoma, which develops in younger patients with a female predominance. 5, 8, 10, 21 Second, a fetal lung-like component in HG-LAFMs was invariably a focal finding accompanied by a histology that did not resemble that of a fetal lung, whereas low-grade adenocarcinoma of the fetal lung type was reported to manifest typically in a pure fetal lung-like form. 10, 11, 21 Third, all of our HG-LAFMs lacked morule formation and aberrant immunoexpression of b-catenin, which are 2 signature findings of low-grade adenocarcinoma of the fetal lung type. 10, 11 We therefore agree with Nakatani et al 8 that low-grade and high-grade lung adenocarcinomas harboring fetal lung-like morphology are completely different diseases, rather than 2 related tumors in the same family differing only in their grades. In this respect, we believe that the current WHO classification system is somewhat confusing because both low-grade and high-grade tumors are read under the same heading by the name of well-differentiated and poorly differentiated fetal adenocarcinoma, respectively. From a practical standpoint, careful wording is necessary when discussing fetal lung-like morphology in a report of highgrade tumors in order to avoid confusion with low-grade adenocarcinoma. We elected to use HG-LAFM terminology in this report because of the concern that the originally proposed "high-grade adenocarcinoma of fetal lung type" 8 terminology might give an inaccurate impression of its relatedness with low-grade adenocarcinoma of fetal lung type.
Coexisting non-fetal lung-like histology in HG-LAFM was quite heterogenous, and it included all 4 common growth patterns of conventional adenocarcinoma: lepidic, papillary, acinar, and solid patterns. Nonetheless, our data suggest that fetal lung-like differentiation has a peculiar tendency to admix with particular non-fetal lunglike morphologic attributes. Specifically, hepatoid morphology and clear-cell pattern, 2 uncommon phenotypes in lung adenocarcinoma, [14] [15] [16] [17] [18] appeared to be overrepresented in the non-fetal lung-like component. These results suggest that fetal lung-like morphology might not be a mere capricious phenotypic variation that any given lung cancer might display, but it might represent a line of differentiation that only a particular subset of lung cancer can undergo.
In agreement with a previous study, 8 we showed that as many as approximately 80% of HG-LAFMs displayed immunohistochemical evidence of neuroendocrine differentiation. Although immunoreactivity to neuroendocrine markers can be seen in 16% to 36% of morphologically nondescript lung adenocarcinomas, [22] [23] [24] the rate of positivity appeared high in HG-LAFMs, which suggests a clearer tendency of neuroendocrine differentiation in this tumor subset. Supporting this hypothesis, 4 of 17 HG-LAFMs in our series displayed morphologic evidence of neuroendocrine differentiation in the form of admixture with LCNEC. In no report of the relevant literature has HG-LAFM with LCNEC component been clearly described, although 1 putative example of HG-LAFM 6 was reportedly associated with "carcinoid-like neuroendocrine component," and the latter element might meet the contemporary criteria of LCNEC.
An increased level of serum AFP was identified in 4 of 5 cases tested. Immunohistochemical AFP staining was demonstrated in 8 cases (47%). This observation is consistent with those of a previous study 8 in which 29% of HG-LAFM demonstrated AFP immunoexpression. AFP production in adenocarcinoma was reported in many other organ systems, and it has been documented most commonly in stomach cancers. AFP-producing stomach cancer is known to occur in elderly patients, and it is characterized by prominent vascular invasion and frequent liver metastasis. [25] [26] [27] [28] Previous histologic analyses of AFP-producing gastric carcinoma have identified several characteristic morphologic patterns: primitive gut (enteroblastic), hepatoid, clear-cell, and yolk sac tumor like. [26] [27] [28] [29] [30] It is particularly interesting that the histology of primitive gut-type (enteroblastic) stomach cancer was described and illustrated as having a complex glandular structure lined by columnar cells with clear cytoplasm. [26] [27] [28] 30 To a great degree, its morphology overlaps fetal lung-like histology that we describe in lung cancer (compare our Figs. 1A and B with the histology of AFPproducing stomach cancers depicted in Image 2 of Maitra et al, 26 Figure 2 The histologic analogy between lung and stomach cancers is strengthened further by the frequent coexistence of hepatoid and clear-cell patterns in our HG-LAFMs, because these 2 patterns are also common in AFP-producing stomach cancers. [26] [27] [28] [29] [30] [31] [32] Immunohistochemical analysis provided yet another support for this parallel, in that GPC-3 and SALL-4, 2 sensitive markers of AFP-producing stomach cancer, 29, 31, 32 are often expressed in HG-LAFMs. The lung and stomach are both developed from the foregut, and AFP-producing stomach cancer and HG-LAFM (which might also produce AFP) might be regarded as showing similar oncofetal retrograde differentiation in terms of its morphology and immunoprofile. Intestinal marker CDX-2 expression, identified in 35% of our HG-LAFMs, might further suggest a close link between fetal lung-like histology in lung cancer and "primitive gut" differentiation in stomach cancer, because AFP-producing stomach cancers are usually of intestinal type and are positive for CDX-2. 33, 34 Results of molecular analysis suggest that HG-LAFM is not genetically homogenous. One case (7% of 14 cases tested) showed EGFR mutation. Another (11% of 9 cases tested) harbored KRAS mutation. However, it is notable that 78% of the 9 cases tested were of wild type for both EGFR and KRAS. Given the high frequency of EGFR and KRAS mutations (46% to 64% and 13%, respectively) in lung adenocarcinoma in the Japanese population, [35] [36] [37] this low rate might be worth investigation. The majority of HG-LAFMs (65%) showed positive p53 immunostaining. The rate of positivity in HG-LAFMs seems higher than that in lung adenocarcinoma in general (44% to 50%). 38, 39 In conclusion, HG-LAFM is associated with several characteristic clinicopathologic features such as male predominance, heavy smoking exposure, overrepresented coexistence with hepatoid, clear-cell, and high-grade neuroendocrine histology, and frequent immunoreactivity to neuroendocrine and oncofetal markers. Confirming the results in the original report 8 and providing additional morphologic and immunophenotypic characterization, our data indicate that HG-LAFMs might form a coherent subgroup of lung adenocarcinomas. However, the uniformly focal nature of fetal lung-like elements, widely diverse coexisting non-fetal lung-like histology, and inhomogenous molecular profiles make us hesitate to conclude that HG-LAFM truly constitutes a specific entity that is worthy of a separate entry in tumor classification. We believe that HG-LAFM is best considered for the time being as a recognizable morphologic pattern showing characteristic association with several clinicopathologic parameters. This treatment contrasts sharply with low-grade adenocarcinoma of fetal lung type, a distinct variant having homogenous fetal lung-like histology and specific genetic alteration. These 2 diseases should be confused neither in diagnostic reports nor in tumor classification. The morphologic and immunohistochemical similarity between HG-LAFM and AFP-producing stomach cancer is striking. This intriguing resemblance might open a new perspective to our understanding of HG-LAFM. 
